Company profile
ClearPoint Neuro, Inc.
NASDAQ: CLPT · Healthcare · Medical - Devices
#476 of 1,418 Healthcare companies by revenue64th-percentile growth
EA Score
62CFH 51DQ 69GM 75SS 69
v0.1 · 65/100 weight · provisional
↑ growth stability, disclosure history · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$40.6M
Rev growth YoY (TTM)
+26.0%
Net income (FY)
-$25.5M
Employees
172
as of 2026-08-11
Market cap
$436.9M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$37.0M$37.0M2025
Net income-$25.5M-$25.5M2025
Operating income-$24.2M-$24.2M2025
Total assets$97.7M$97.7M2025
Liabilities$69.7M$69.7M2025
Equity$28.0M$28.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Biologics and Drug Delivery Revenue58%
Biologics and Drug Delivery - Disposable Products23%
Capital Equipment and Software Revenue10%
Capital Equipment and Software - Systems and Software Products5%
Capital Equipment and Software - Services4%
By geography
Not disclosed.
The read
What is ClearPoint Neuro, Inc.’s revenue?
ClearPoint Neuro, Inc. booked $37.0M in FY2025 revenue, growing 18% year over year — faster than most Healthcare companies we track, at a -69.1% net margin.
Peers · Healthcare
Utah Medical Products, Inc.80B+Retractable Technologies, Inc.57CCytosorbents Corporation55CSunshine Biopharma, Inc.50DC4 Therapeutics, Inc.49DEarth Science Tech, Inc.69BNeighbors
San Diego →Key facts
CEOJoseph Michael Burnett
SectorHealthcare
IndustryMedical - Devices
HeadquartersSolana Beach, CA
ExchangeNASDAQ: CLPT
Employees172
IPO date2012-05-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.